

Erythropoietin May Improve HF-Related Anemia

BY BRUCE JANCIN

BARCELONA — Erythropoietin therapy in patients with anemia of heart failure resulted in improved exercise capacity, reduced heart failure symptoms, and decreased hospitalizations, and showed strong trends for reduced rates of MI and all-cause mortality in a meta-analysis of 11 small randomized clinical trials.

Moreover, erythropoietin was not as-

sociated with an increased rate of adverse events, as in some clinical trials carried out in the settings of cancer or chronic kidney disease. It may be that erythropoietin's angiogenesis-promoting effect is therapeutic in the context of heart failure but is the source of side effects in patients with cancer or renal disease, Dr. Dipak Kotecha said at the annual congress of the European Society of Cardiology.

He was quick to offer a caveat, however: "This is all based on a relatively small sample size. Some of these trials were small proof-of-concept trials, others were mechanistic and looked at the effects of different doses. None were individually powered for clinical events. The follow-up was relatively short, at 2-12 months."

The 11 randomized trials involved 794 patients with mild to moderate anemia

and left ventricular systolic heart failure. Nine of the trials were placebo controlled. Mean baseline hemoglobin was 10.1-11.8 g/dL and rose by 2.0 g/dL in response to erythropoietin therapy.

This 2.0-g/dL increase in hemoglobin was associated with a mean 69-meter improvement in 6-minute walk distance compared with controls, a 96-second increase in exercise duration, and an improvement in New York Heart Association functional class equivalent to three-quarters of a class.

"All of these changes were clinically as well as statistically highly significant," observed Dr. Kotecha of Royal Brompton Hospital, London.

Peak oxygen consumption, or VO_2 max, increased by an average of 2.3 mL/kg per min. Left ventricular ejection



Heart failure hospitalizations in erythropoietin-treated patients were significantly reduced by 36%.

DR. KOTECHA

fraction increased in erythropoietin-treated patients by an absolute 5.8% compared with controls; that is comparable to the improvement seen in the major clinical trials of beta-blockers. Quality of life scores using the standard Minnesota and Kansas City instruments showed significant gains as well.

Heart failure hospitalizations in erythropoietin-treated patients were significantly reduced by 36% compared with controls, reflecting an absolute 8% rate difference. "The absolute 8% decrease in hospitalizations for heart failure is very similar to what's been seen in the major clinical trials of beta-blocker therapy in heart failure," Dr. Kotecha said.

B-type natriuretic peptide levels fell by an average of 40%, or 237 pg/dL, in response to erythropoietin. Again, that is a magnitude of effect similar to what has been seen in clinical trials of combined beta-blocker and ACE inhibitor or angiotensin receptor blocker therapy, he continued.

The risk of all-cause mortality was reduced by 39% in the erythropoietin treatment group, a strong trend that just missed statistical significance. The 27% relative risk reduction in acute MI also was not quite significant. Definitive answers as to whether erythropoietin therapy has a beneficial effect on these key outcomes are anticipated from the ongoing Amgen-sponsored phase III Reduction of Events With Darbepoetin Alfa in Heart Failure (RED-HF) trial, which is randomizing more than 3,000 patients.

Dr. Kotecha reported having no financial conflicts of interest in connection with the meta-analysis, which was conducted using Cochrane Collaboration methodology and has been submitted to the Cochrane Review for possible publication.

REGISTER NOW

WWW.RHEUMATOLOGYNEWSPERSPECTIVES.COM

FOR A SPECIAL DISCOUNT

VISIT BOOTH #2101 AT AAFP

Rheumatology News® • Family Practice News® • Internal Medicine News®

PRESENT A CONTINUING MEDICAL EDUCATION CONFERENCE

PERSPECTIVES IN RHEUMATIC DISEASES 2009™

DECEMBER 4-5, 2009

Loews Santa Monica Beach Hotel
Santa Monica, California



REGISTRATION

	Before 8/1/2009 Discount Extended to 10/1/2009	After 10/1/2009
Physicians	\$350	\$450
Physician Assistant	\$250	\$350
Nurse Practitioner	\$250	\$350
Residents	\$250	\$350

HOTEL ACCOMMODATIONS

Loews Santa Monica Beach Hotel,
Santa Monica, California, Phone: (310) 458-6700.
Mention **Rheumatology Conference** for preferred rates.

Daniel E. Furst, MD, CHAIR

Carl M. Pearson Professor of Medicine
Department of Medicine, Division of Rheumatology
David Geffen School of Medicine at the
University of California, Los Angeles (UCLA)

Kenneth B. Gordon, MD, CO-CHAIR

Head, Division of Dermatology
NorthShore University HealthSystem
Northwestern University Feinberg School of
Medicine, Chicago

PROGRAM HIGHLIGHTS*

Predicting the Course of RA	Juvenile Idiopathic Arthritis
Co-Morbid Conditions and RA	Psoriasis Update
Vaccine Use in Vulnerable Patients	Psoriatic Arthritis
Gout and Hyperuricemia	Cutaneous Lupus: Better Outcomes
Systemic Scleroderma	Cardiovascular Risk Factors in RA
Rheumatic Diseases and IBD	Fibromyalgia
Steroid-Induced Osteoporosis	Update on Osteoarthritis
Managing Your Practice	Interactive Clinical Cases

FACULTY

Roy D. Altman, MD, University of California, Los Angeles
Clifton O. Bingham, III, MD, Johns Hopkins University
Chad S. Boomer, MD, PhD, Vanderbilt University
John J. Cush, MD, Baylor University Medical Center
Joseph S. Eastern, MD, UMDNJ & Seton Hall University
David F. Fiorentino, MD, PhD, Stanford University School of Medicine
Daniel E. Furst, MD, University of California, Los Angeles
Kenneth B. Gordon, MD, Northwestern University
Thomas J.A. Lehman, MD, Cornell University
Kimberly P. Liang, MD, University of Pittsburgh
Brian Mandell, MD, PhD, Cleveland Clinic
Soumya M. Reddy, MD, New York University
Bennett Roth, MD, University of California, Los Angeles
Kenneth G. Saag, MD, MSc, University of Alabama at Birmingham

*Program subject to change. Go to conference website for updates.

Target Audience

This continuing medical education conference is designed for rheumatologists, internists, family practice physicians and healthcare professionals involved in the treatment of patients with rheumatic diseases.

Learning Objectives

At the conclusion of this conference, participants will be able to:

- Identify the therapeutic options in the management of rheumatic diseases
- Explain the connection between rheumatic diseases and CV risk
- Recognize the aspects of care, treatment, and overall outcomes that are important to pediatric patients
- Describe the long-term safety and efficacy of systemic and biologic agents in the treatment of psoriasis and psoriatic arthritis
- Evaluate patients to determine their risk for disease progression
- Recognize and describe the clinical manifestations and complications of scleroderma
- Develop a strategy for a diagnostic workup for fibromyalgia
- Discuss the challenges in managing the RA patient with IBD
- Explain the clinical manifestations and risk factors associated with gout

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Skin Disease Education Foundation (SDEF). The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians.

AMA PRA Credit Designation Statement

The EOCME designates this educational activity for a maximum of 11 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AAFP accreditation

This activity has been reviewed and is acceptable for up to 10.5 Prescribed credit(s) by the American Academy of Family Physicians.

Jointly sponsored by



Other Publication Partners



Supported in part by grants from



For more information go to
www.rheumatologynewsperspectives.com or call 973.290.8225